Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for Thursday, December 5, 2024, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's investor and media section website, with replay available approximately two hours after completion and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels effectively, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid). The analysis showed patients with Peripheral Artery Disease (PAD) taking bempedoic acid were 36% less likely to experience major adverse limb events compared to placebo. Additional data revealed that after 3 months, 67% of patients using bempedoic acid and ezetimibe combination achieved LDL-C levels below 100 mg/dL, with 55% maintaining these levels at 12 months.
Esperion (NASDAQ: ESPR) has granted 12,900 restricted stock units (RSUs) to four new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter. These grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in accordance with NASDAQ Listing Rule 5635(c)(4). The vesting is contingent upon continued employment with Esperion.
Esperion (ESPR) reported strong Q3 2024 financial results with total revenue increasing 52% year-over-year to $51.6 million. U.S. net product revenue grew 53% to $31.1 million, driven by retail prescription growth. Total retail prescription equivalents increased 12% and new to brand prescriptions grew 18% from Q2. The company expanded product labels, scaled up commercial team, and strengthened balance sheet by monetizing European royalties. Over 165 million lives now have updated utilization management criteria aligned to new labels across Commercial, Medicare and Medicaid payers. Cash and cash equivalents totaled $144.7 million as of September 30, 2024.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Jefferies London Healthcare Conference scheduled for Tuesday, November 19, 2024, at 11:30 a.m. ET. The event will be webcasted live on Esperion's investor and media section website, with replay access available approximately two hours after the call and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels as effectively as possible, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (NASDAQ: ESPR) announced the acceptance of four presentations at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. The presentations include one featured presentation in the Late Breaker/Featured Science track focusing on bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease from the CLEAR Outcomes Trial. Additionally, three poster presentations will cover liver steatosis and cardiovascular events, statin intolerance effects on patient management, and real-world effectiveness of bempedoic acid plus ezetimibe therapy.
Esperion (NASDAQ: ESPR) has announced it will report its third quarter 2024 financial results on Thursday, November 7, 2024, before market opens. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. A live audio webcast will be accessible through Esperion's website, with the replay available for approximately 90 days after the call. The company focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol treatment.
Esperion announced final 2-year follow-up data from the German cohort of the MILOS study, evaluating real-world use of bempedoic acid in patients with primary hypercholesterolemia or mixed dyslipidemia. The study showed:
- A 30.3% average relative reduction in LDL-C levels from pre-treatment to 2 years
- An increase in patients reaching LDL-C goals from 4.9% to 35.3% at 2-year follow-up
- Over 80% of patients received bempedoic acid with other lipid-lowering therapies
- Safety profile consistent with the CLEAR clinical trial program
The data demonstrates the effectiveness of bempedoic acid in real-world settings, supporting its role in helping patients achieve LDL-C goals and potentially reducing cardiovascular event risks.
Esperion (NASDAQ: ESPR) announced on September 25, 2024, that it granted 3,500 restricted stock units (RSUs) to a new employee on September 23, 2024, under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for granting equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET. The event will be webcasted live and accessible through Esperion's investor and media website section. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a company focused on discovering, developing, and commercializing innovative medicines for patients with or at risk of cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next steps in LDL-cholesterol reduction.